ORCA Therapeutics B.V. is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents (ORCA).

These agents are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells,
while healthy cells are left unharmed. In addition, oncolytic viruses are used as efficient delivery agents to express anti-cancer products at high levels in cancer cells and as anti-cancer vaccines that present cancer antigens to the immune system.

 
 

News

20 March 2013
ORCA Therapeutics BV announced that it has secured key intellectual property rights for its T1 oncolytic adenovirus technology.

read more +

 

Events

There are no current events at this moment.
 

Job Opportunities

There are no vacancies.
 

   

Terms of use | Disclaimer | Contact

© 2009 ORCA Therapeutics B.V. | Photography: Wen L. Dong, PhD